CD22 and neoplasm: HCC-1954 breast tumor bearing mice were treated intravenously with a single injection of anti-Her2 position 1-ADC(0.5, 1 or 3.3 mg/kg), anti-Her2 position 2-ADC (0.5 or 1 mg/kg), anti-Her2 Cys-ADC (0.5, 1 or 3.3 mg/kg) or the control ADCs (Anti-CD22 position 1-ADC or Anti-CD22-Cys-ADC at 3.3 mg/kg) or Vehicle (5% Dextrose) when the average tumor size reached approximately 200 mm3.